Compound Radar

Moderna, Inc. (MRNA) Stock Analysis

United States · Healthcare / Biotechnology

Price $140.33
Market cap $56.02B
Next earnings Nov 5, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

36
36/100 Avoid
  • Financial Health 40
  • Profitability 5
  • Business Quality 55
  • Balance Sheet 45
  • Cash Flow 25

Why this rating?

Health 36/100 — Avoid

Strongest Business Quality 55/100
Softest Profitability 5/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Moderna, Inc. (MRNA) is a Biotechnology company in the Healthcare sector. Compound Radar rates Moderna, Inc. 36/100 (Avoid) due to solid business quality, steady revenue growth, and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Moderate
  • Balance Sheet Stretched

Financial highlights

Valuation

  • Forward P/E -30.56
  • EV/Revenue 24.35

Profitability

  • Revenue Growth 2.1%
  • Gross Margin -66.0%
  • Operating Margin -557.9%
  • Net Margin -141.4%
  • ROE -39.0%

Financial strength

  • Cash $5.14B
  • Debt $1.29B
  • Net Cash $3.85B
  • Free Cash Flow $-2.08B
  • Current Ratio 2.3

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Moderna, Inc. (MRNA).

View Methodology & FAQ →